Objectives: To demonstrate the efficacy and safety of ATGC-110 in the treatment of subjects with moderate-to-severe glabellar lines (GLs).
Introduction: This was a multicenter, randomized, double-blind, active-controlled, non-inferiority, phase 3 clinical trial comparing the efficacy and safety of 20 units (U) of ATGC-110 and 20 U of incobotulinumtoxinA in the treatment of subjects with moderate-to-severe GLs.
Materials / method: Baseline (BL) and post-treatment assessments were made using a validated 4-point facial wrinkle scale (FWS), a 9-point subject global assessment of change scale (GACS), and a 7-point subject satisfaction assessment scale (SSAS). Primary efficacy was assessed for the per protocol set (PPS) at Week 4 and was the proportion of subjects with 0 (none) or 1 (mild) on the FWS at maximum frown and improvement of at least 2-points from BL based on the investigator’s live assessment. Secondary efficacy endpoints and adverse events also were assessed.
Results: Subjects (N=298) had a mean (SD) age of 48.6 (8.77) years and were mostly female (79.9%) and moderate (63.1%) in GL severity at BL. For ATGC-110 subjects, 85.1% were responders on the primary endpoint compared to 68.1% for incobotulinumtoxinA subjects (p=0.0010). The difference of proportion [95% CI] was 0.17 [0.06, 0.27]; CI lower bound exceeded the non-inferiority margin of -0.15. Additional efficacy results to be reported to Week 16. Treatment-emergent adverse events (TEAEs) were mostly mild and occurred at similar frequencies among ATGC-110 (9.4%) and incobotulinumtoxinA (6.6%) subjects.
Conclusion: ATGC-110 is a novel, investigational, 150 kDa botulinum neurotoxin type A drug product, free of neurotoxin associated proteins (NAPs). In this Korean phase 3 trial, ATGC-110 significantly reduced GL severity and was associated with a favorable safety profile. ATGC-110 was shown to be non-inferior to incobotulinumtoxinA in the treatment of moderate-to-severe GLs at Week 4.
Divulgação de informações
Você recebeu algum patrocínio para sua pesquisa neste tema?
Não
Você recebeu algum tipo de honorário, pagamento ou outra forma de compensação por seu trabalho neste estudo?
Sim
Por favor indique a entidade (pessoa ou empresa): I am an employee of Sinclair
Você possui relação financeira com alguma entidade que possa competir com os medicamentos, materiais ou instrumentos abordados no seu estudo?
Não
Você detém ou pediu a registro de patente para algum dos instrumentos, medicamentos ou materiais abordados no seu estudo?
Não
Este trabalho foi realizado com o patrocínio de: Sinclair and ATGC Co., Ltd